BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one? J Pharmacol Exp Ther. 2010;332:692-697. [PMID: 20019161 DOI: 10.1124/jpet.109.162651] [Cited by in Crossref: 99] [Cited by in F6Publishing: 78] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Bale SS, Vernetti L, Senutovitch N, Jindal R, Hegde M, Gough A, McCarty WJ, Bakan A, Bhushan A, Shun TY, Golberg I, DeBiasio R, Usta BO, Taylor DL, Yarmush ML. In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood) 2014;239:1180-91. [PMID: 24764241 DOI: 10.1177/1535370214531872] [Cited by in Crossref: 107] [Cited by in F6Publishing: 97] [Article Influence: 13.4] [Reference Citation Analysis]
2 Moulin F, Flint O. In Vitro Models for the Prediction of Drug-Induced Liver Injury in Lead Discovery. In: Urbán L, Patel VF, Vaz RJ, editors. Antitargets and Drug Safety. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2015. pp. 125-58. [DOI: 10.1002/9783527673643.ch07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Benesic A, Jalal K, Gerbes AL. Drug-Drug Combinations Can Enhance Toxicity as Shown by Monocyte-Derived Hepatocyte-like Cells From Patients With Idiosyncratic Drug-Induced Liver Injury. Toxicological Sciences 2019;171:296-302. [DOI: 10.1093/toxsci/kfz156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Funk C, Roth A. Current limitations and future opportunities for prediction of DILI from in vitro. Arch Toxicol 2017;91:131-42. [DOI: 10.1007/s00204-016-1874-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
5 Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol 2014; 6(8): 601-612 [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.601] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
6 Foster JR, Jacobsen M, Kenna G, Schulz-utermoehl T, Morikawa Y, Salmu J, Wilson ID. Differential Effect of Troglitazone on the Human Bile Acid Transporters, MRP2 and BSEP, in the PXB Hepatic Chimeric Mouse. Toxicol Pathol 2012;40:1106-16. [DOI: 10.1177/0192623312447542] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
7 Mohutsky MA, Romeike A, Meador V, Lee WM, Fowler J, Francke-carroll S. Hepatic Drug-Metabolizing Enzyme Induction and Implications for Preclinical and Clinical Risk Assessment. Toxicol Pathol 2010;38:799-809. [DOI: 10.1177/0192623310375099] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
8 Chavan S, Scherbak N, Engwall M, Repsilber D. Predicting Chemical-Induced Liver Toxicity Using High-Content Imaging Phenotypes and Chemical Descriptors: A Random Forest Approach. Chem Res Toxicol 2020;33:2261-75. [DOI: 10.1021/acs.chemrestox.9b00459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kenna JG, Thompson RA. INTEGRATED REACTIVE METABOLITE STRATEGIES. In: Iverson SL, Smith DA, editors. Metabolite Safety in Drug Development. Hoboken: John Wiley & Sons, Inc.; 2016. pp. 111-39. [DOI: 10.1002/9781118949689.ch5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Rao T, Liu YT, Zeng XC, Li CP, Ou-Yang DS. The hepatotoxicity of Polygonum multiflorum: The emerging role of the immune-mediated liver injury. Acta Pharmacol Sin. 2021;42:27-35. [PMID: 32123300 DOI: 10.1038/s41401-020-0360-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Hewitt M, Enoch SJ, Madden JC, Przybylak KR, Cronin MTD. Hepatotoxicity: A scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action. Critical Reviews in Toxicology 2013;43:537-58. [DOI: 10.3109/10408444.2013.811215] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 6.2] [Reference Citation Analysis]
12 Bakhati B, Sibi VM, Mekala AP, Ronen JA, Mungara S. What Is Uncommon Can Be Critical: A Case of Quinolone-Induced Acute Liver Failure. Cureus 2021;13:e14780. [PMID: 34094745 DOI: 10.7759/cureus.14780] [Reference Citation Analysis]
13 Lee SJ, Lee YJ, Park KK. The pathogenesis of drug-induced liver injury. Expert Rev Gastroenterol Hepatol 2016;10:1175-85. [PMID: 27248313 DOI: 10.1080/17474124.2016.1196133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
14 Roth RA, Maiuri AR, Ganey PE. Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin? J Pharmacol Exp Ther 2017;360:461-70. [PMID: 28104833 DOI: 10.1124/jpet.116.237578] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
15 Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M. Current Challenges and Controversies in Drug-Induced Liver Injury. Drug Saf 2012;35:1099-117. [DOI: 10.1007/bf03261997] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
16 Norman BH. Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. J Med Chem 2020;63:11397-419. [PMID: 32511920 DOI: 10.1021/acs.jmedchem.0c00524] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
17 Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892-913. [PMID: 30194708 DOI: 10.1111/apt.14952] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
18 Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, Kenna JG. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 2011;192:65-71. [PMID: 21074519 DOI: 10.1016/j.cbi.2010.11.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
19 Chen M, Borlak J, Tong W. Predicting idiosyncratic drug-induced liver injury - some recent advances. Expert Rev Gastroenterol Hepatol. 2014; May 23. [Epub ahead of print]. [PMID: 24857265 DOI: 10.1586/17474124.2014.922871] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
20 Heidari R, Niknahad H, Jamshidzadeh A, Abdoli N. Factors affecting drug-induced liver injury: antithyroid drugs as instances. Clin Mol Hepatol 2014;20:237-48. [PMID: 25320726 DOI: 10.3350/cmh.2014.20.3.237] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
21 Dalvie D, Kalgutkar AS, Chen W. Practical approaches to resolving reactive metabolite liabilities in early discovery. Drug Metabolism Reviews 2015;47:56-70. [DOI: 10.3109/03602532.2014.984813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
22 Hedenmalm K, Pacurariu A, Slattery J, Kurz X, Candore G, Flynn R. Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users. Drug Saf 2021;44:973-85. [PMID: 34273099 DOI: 10.1007/s40264-021-01087-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Raschi E, De Ponti F. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Front Pharmacol 2019;10:1235. [PMID: 31708776 DOI: 10.3389/fphar.2019.01235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
24 Hadi M, Chen Y, Starokozhko V, Merema MT, Groothuis GM. Mouse Precision-Cut Liver Slices as an ex Vivo Model To Study Idiosyncratic Drug-Induced Liver Injury. Chem Res Toxicol 2012;25:1938-47. [DOI: 10.1021/tx300248j] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
25 Howell LS, Ireland L, Park BK, Goldring CE. MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury. Expert Rev Mol Diagn 2018;18:47-54. [PMID: 29235390 DOI: 10.1080/14737159.2018.1415145] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
26 Stephens C, Lucena MI, Andrade RJ. Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. In: Chen M, Will Y, editors. Drug-Induced Liver Toxicity. New York: Springer; 2018. pp. 477-96. [DOI: 10.1007/978-1-4939-7677-5_23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Rathman J, Yang C, Ribeiro JV, Mostrag A, Thakkar S, Tong W, Hobocienski B, Sacher O, Magdziarz T, Bienfait B. Development of a Battery of In Silico Prediction Tools for Drug-Induced Liver Injury from the Vantage Point of Translational Safety Assessment. Chem Res Toxicol 2021;34:601-15. [PMID: 33356149 DOI: 10.1021/acs.chemrestox.0c00423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Patel SJ, Milwid JM, King KR, Bohr S, Iracheta-Velle A, Li M, Vitalo A, Parekkadan B, Jindal R, Yarmush ML. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol. 2012;30:179-183. [PMID: 22252509 DOI: 10.1038/nbt.2089] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 8.2] [Reference Citation Analysis]
29 Gómez-Lechón MJ, Tolosa L, Donato MT. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol 2016;36:752-68. [PMID: 26691983 DOI: 10.1002/jat.3277] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
30 Han D, Dara L, Win S, Than TA, Yuan L, Abbasi SQ, Liu ZX, Kaplowitz N. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria.Trends Pharmacol Sci. 2013;34:243-253. [PMID: 23453390 DOI: 10.1016/j.tips.2013.01.009] [Cited by in Crossref: 112] [Cited by in F6Publishing: 98] [Article Influence: 12.4] [Reference Citation Analysis]
31 Mitchell SJ, Kane AE, Hilmer SN. Age-related changes in the hepatic pharmacology and toxicology of paracetamol. Curr Gerontol Geriatr Res 2011;2011:624156. [PMID: 21765826 DOI: 10.1155/2011/624156] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
32 Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W. Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomark Med. 2014;8:201-213. [PMID: 24521015 DOI: 10.2217/bmm.13.146] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 11.6] [Reference Citation Analysis]
33 Namn Y, Schneider Y, Cui IH, Jesudian A. Diphenhydramine as a Cause of Drug-Induced Liver Injury. Case Reports Hepatol 2017;2017:3864236. [PMID: 28246565 DOI: 10.1155/2017/3864236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
34 Ahn JH, Jegal H, Choi MS, Kim S, Park SM, Ahn J, Han HY, Cho HS, Yoon S, Oh JH. TNFα enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett 2021;342:73-84. [PMID: 33609687 DOI: 10.1016/j.toxlet.2021.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Doß S, Potschka H, Doß F, Mitzner S, Sauer M. Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results. Biomed Res Int 2017;2017:9658018. [PMID: 28473992 DOI: 10.1155/2017/9658018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
36 Sison-young R, Kia R, Heslop J, Kelly L, Rowe C, Cross M, Kitteringham N, Hanley N, Park B, Goldring C. Human Pluripotent Stem Cells for Modeling Toxicity. Current Concepts in Drug Metabolism and Toxicology. Elsevier; 2012. pp. 207-56. [DOI: 10.1016/b978-0-12-398339-8.00006-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
37 Serras AS, Rodrigues JS, Cipriano M, Rodrigues AV, Oliveira NG, Miranda JP. A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies. Front Cell Dev Biol 2021;9:626805. [PMID: 33732695 DOI: 10.3389/fcell.2021.626805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Roth RA, Ganey PE. Animal models of idiosyncratic drug-induced liver injury—Current status. Critical Reviews in Toxicology 2011;41:723-39. [DOI: 10.3109/10408444.2011.575765] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
39 Shamseddeen H, Vilar-Gomez E, Chalasani N, Myers RP, Subramanian GM, Shlevin HH, Allgood AE, Orman ES. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring. Drug Saf 2020;43:281-90. [PMID: 31907854 DOI: 10.1007/s40264-019-00896-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Ommati MM, Mobasheri A, Heidari R. Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. J Biochem Mol Toxicol 2021;35:e22795. [PMID: 33973313 DOI: 10.1002/jbt.22795] [Reference Citation Analysis]
41 Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG. In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. Chem Res Toxicol 2012;25:1616-32. [DOI: 10.1021/tx300091x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 124] [Article Influence: 15.7] [Reference Citation Analysis]
42 Brooks A, Liang X, Zhang Y, Zhao CX, Roberts MS, Wang H, Zhang L, Crawford DHG. Liver organoid as a 3D in vitro model for drug validation and toxicity assessment. Pharmacol Res 2021;169:105608. [PMID: 33852961 DOI: 10.1016/j.phrs.2021.105608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Granitzny A, Knebel J, Schaudien D, Braun A, Steinberg P, Dasenbrock C, Hansen T. Maintenance of high quality rat precision cut liver slices during culture to study hepatotoxic responses: Acetaminophen as a model compound. Toxicol In Vitro 2017;42:200-13. [PMID: 28476500 DOI: 10.1016/j.tiv.2017.05.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
44 Salva I, Silva IV, Cunha F. Epstein-Barr virus-associated cholestatic hepatitis. BMJ Case Rep 2013;2013:bcr2013202213. [PMID: 24343806 DOI: 10.1136/bcr-2013-202213] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
45 Liguori MJ, Ditewig AC, Maddox JF, Luyendyk JP, Lehman-McKeeman LD, Nelson DM, Bhaskaran VM, Waring JF, Ganey PE, Roth RA, Blomme EA. Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example. Int J Mol Sci 2010;11:4697-714. [PMID: 21151465 DOI: 10.3390/ijms11114697] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
46 Mirahmad M, Sabourian R, Mahdavi M, Larijani B, Safavi M. In vitro cell-based models of drug-induced hepatotoxicity screening: progress and limitation. Drug Metab Rev 2022;:1-76. [PMID: 35403528 DOI: 10.1080/03602532.2022.2064487] [Reference Citation Analysis]
47 Hughes DJ, Kostrzewski T, Sceats EL. Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems. Exp Biol Med (Maywood) 2017;242:1593-604. [PMID: 28504617 DOI: 10.1177/1535370217708976] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
48 Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010;118:7-18. [PMID: 20538741 DOI: 10.1093/toxsci/kfq168] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 7.0] [Reference Citation Analysis]
49 Hosoya M, Czysz K. Translational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug Discovery. Cells 2016;5:E46. [PMID: 28009813 DOI: 10.3390/cells5040046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
50 Granitzny A, Knebel J, Müller M, Braun A, Steinberg P, Dasenbrock C, Hansen T. Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: A pilot study. Toxicol Rep 2017;4:89-103. [PMID: 28959630 DOI: 10.1016/j.toxrep.2017.02.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
51 Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S. Current challenges and controversies in drug-induced liver injury. Drug Saf. 2012;35:1099-1117. [PMID: 23137150 DOI: 10.2165/11632970-000000000-00000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Niknahad H, Heidari R, Firuzi R, Abazari F, Ramezani M, Azarpira N, Hosseinzadeh M, Najibi A, Saeedi A. Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats. Adv Pharm Bull. 2016;6:617-625. [PMID: 28101469 DOI: 10.15171/apb.2016.076] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
53 Urano Y, Oda S, Tsuneyama K, Yokoi T. Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. Chemico-Biological Interactions 2018;296:185-97. [DOI: 10.1016/j.cbi.2018.09.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Zhang C, Cheng F, Li W, Liu G, Lee PW, Tang Y. In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method. Mol Inform 2016;35:136-44. [PMID: 27491923 DOI: 10.1002/minf.201500055] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
55 Raschi E, Poluzzi E, Koci A, Caraceni P, De Ponti F. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601-612. [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.60] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Tong HY, Medrano N, Borobia AM, Martínez AM, Martín J, Ruiz JA, García S, Quintana M, Carcas AJ, Frías J, Ramírez E. Hepatotoxicity induced by acute and chronic paracetamol overdose in adults. Where do we stand? Regul Toxicol Pharmacol 2015;72:370-8. [PMID: 25985715 DOI: 10.1016/j.yrtph.2015.05.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
57 Mitchell SJ, Hilmer SN. Drug-induced liver injury in older adults. Ther Adv Drug Saf 2010;1:65-77. [PMID: 25083196 DOI: 10.1177/2042098610386281] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
58 Gamal W, Treskes P, Samuel K, Sullivan GJ, Siller R, Srsen V, Morgan K, Bryans A, Kozlowska A, Koulovasilopoulos A, Underwood I, Smith S, Del-Pozo J, Moss S, Thompson AI, Henderson NC, Hayes PC, Plevris JN, Bagnaninchi PO, Nelson LJ. Low-dose acetaminophen induces early disruption of cell-cell tight junctions in human hepatic cells and mouse liver. Sci Rep 2017;7:37541. [PMID: 28134251 DOI: 10.1038/srep37541] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
59 Dinis-Oliveira RJ. Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity. Drug Metab Rev 2021;:1-9. [PMID: 33905271 DOI: 10.1080/03602532.2021.1917599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Shah F, Leung L, Barton HA, Will Y, Rodrigues AD, Greene N, Aleo MD. Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays. Toxicol Sci 2015;147:500-14. [DOI: 10.1093/toxsci/kfv152] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 10.7] [Reference Citation Analysis]
61 Roth RA, Ganey PE. Role of Inflammation in Drug-Induced Liver Injury. Drug-Induced Liver Disease. Elsevier; 2013. pp. 157-73. [DOI: 10.1016/b978-0-12-387817-5.00010-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
62 Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63:503-514. [PMID: 25912521 DOI: 10.1016/j.jhep.2015.04.016] [Cited by in Crossref: 200] [Cited by in F6Publishing: 175] [Article Influence: 28.6] [Reference Citation Analysis]
63 Sarkar U, Rivera-Burgos D, Large EM, Hughes DJ, Ravindra KC, Dyer RL, Ebrahimkhani MR, Wishnok JS, Griffith LG, Tannenbaum SR. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos. 2015;43:1091-1099. [PMID: 25926431 DOI: 10.1124/dmd.115.063495] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
64 Rubiano A, Indapurkar A, Yokosawa R, Miedzik A, Rosenzweig B, Arefin A, Moulin CM, Dame K, Hartman N, Volpe DA, Matta MK, Hughes DJ, Strauss DG, Kostrzewski T, Ribeiro AJS. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation. Clin Transl Sci 2021;14:1049-61. [PMID: 33382907 DOI: 10.1111/cts.12969] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
65 Kopilakkal R, Musuvathi BM. Evaluation of Hepatoprotective Activity of <i>Clerodendrum paniculatum</i> Leaf on Carbon Tetrachloride-Induced Liver Toxicity Model in Swiss Albino Rats and Its Characterization by GC-MS. Endocr Metab Immune Disord Drug Targets 2020;20:1097-109. [PMID: 32164520 DOI: 10.2174/1871530320666200312152331] [Reference Citation Analysis]
66 Karimi G, Star K, Norén GN, Hägg S. The impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilance. PLoS One 2013;8:e68938. [PMID: 23869234 DOI: 10.1371/journal.pone.0068938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
67 Heidari R, Niknahad H, Jamshidzadeh A, Eghbal MA, Abdoli N. An overview on the proposed mechanisms of antithyroid drugs-induced liver injury. Adv Pharm Bull 2015;5:1-11. [PMID: 25789213 DOI: 10.5681/apb.2015.001] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
68 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
69 Walles M, Brown AP, Zimmerlin A, End P. New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl Glucuronides. Chem Res Toxicol 2020;33:1551-60. [PMID: 32525307 DOI: 10.1021/acs.chemrestox.0c00131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
70 Delgado-montemayor C, Cordero-pérez P, Salazar-aranda R, Waksman-minsky N. Models of hepatoprotective activity assessment. Medicina Universitaria 2015;17:222-8. [DOI: 10.1016/j.rmu.2015.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
71 Jing J, Teschke R. Traditional Chinese Medicine and Herb-induced Liver Injury: Comparison with Drug-induced Liver Injury. J Clin Transl Hepatol 2018;6:57-68. [PMID: 29577033 DOI: 10.14218/JCTH.2017.00033] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
72 Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914-928. [PMID: 24389305 DOI: 10.1053/j.gastro.2013.12.032] [Cited by in Crossref: 147] [Cited by in F6Publishing: 131] [Article Influence: 16.3] [Reference Citation Analysis]
73 van Swelm RPL, Kramers C, Masereeuw R, Russel FGM. Application of urine proteomics for biomarker discovery in drug-induced liver injury. Critical Reviews in Toxicology 2014;44:823-41. [DOI: 10.3109/10408444.2014.931341] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
74 Chen Z, Jiang Y, Zhang X, Zheng R, Qiu R, Sun Y, Zhao C, Shang H. ResNet18DNN: prediction approach of drug-induced liver injury by deep neural network with ResNet18. Brief Bioinform 2021:bbab503. [PMID: 34882224 DOI: 10.1093/bib/bbab503] [Reference Citation Analysis]
75 Liu X, Chen C, Zhang X. Drug-drug interaction of acetaminophen and roxithromycin with the cocktail of cytochrome P450 and hepatotoxicity in rats. Int J Med Sci 2020;17:414-21. [PMID: 32132876 DOI: 10.7150/ijms.38527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Sohal A, Alhankawi D, Sandhu S, Chintanaboina J. Turmeric-Induced Hepatotoxicity: Report of 2 Cases. Int Med Case Rep J 2021;14:849-52. [PMID: 34992472 DOI: 10.2147/IMCRJ.S333342] [Reference Citation Analysis]
77 Uehara T, Kosyk O, Jeannot E, Bradford BU, Tech K, Macdonald JM, Boorman GA, Chatterjee S, Mason RP, Melnyk SB. Acetaminophen-induced acute liver injury in HCV transgenic mice. Toxicol Appl Pharmacol. 2013;266:224-232. [PMID: 23200774 DOI: 10.1016/j.taap.2012.11.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
78 Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants (Basel) 2021;10:390. [PMID: 33807700 DOI: 10.3390/antiox10030390] [Reference Citation Analysis]
79 Kim NS, Shin S, Shin GG, Bang OS. Genotoxicity evaluation of a Phragmitis rhizoma extract using a standard battery of in vitro and in vivo assays. J Ethnopharmacol 2019;241:112025. [PMID: 31189082 DOI: 10.1016/j.jep.2019.112025] [Reference Citation Analysis]
80 Usta OB, McCarty WJ, Bale S, Hegde M, Jindal R, Bhushan A, Golberg I, Yarmush ML. Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies. Technology (Singap World Sci) 2015;3:1-26. [PMID: 26167518 DOI: 10.1142/S2339547815300012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
81 Dinis-Oliveira RJ, Vieira DN. Acute liver failure requiring transplantation: A possible link to ulipristal acetate treatment? Basic Clin Pharmacol Toxicol 2021;129:278-82. [PMID: 34187080 DOI: 10.1111/bcpt.13631] [Reference Citation Analysis]
82 Kenakin TP. Safety Pharmacology. Pharmacology in Drug Discovery. Elsevier; 2012. pp. 211-27. [DOI: 10.1016/b978-0-12-384856-7.00010-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]